募资5亿美元加码核心管线!Avidity(RNA.US)获美银唱好 目标价看高至65美元

智通财经
Sep 15, 2025

智通财经APP获悉,美国银行发表研报,予以Avidity Biosciences Inc. (RNA.US)“买入”评级,并将目标价从56美元上调至65美元。按该公司最新收盘价计算,新目标价意味着其股价仍有45%的上涨空间。

该行表示,Avidity Biosciences当前股价的回调,为投资者提供了大举增持该股的重要机遇。得益于分析师上调其股票目标价及评级,Avidity Biosciences上周五终结了连续四日的下跌趋势,股价收涨9.02%。

此次评级与目标价调整,源于Avidity Biosciences此前宣布拟发行价值5亿美元的股票。募集资金将用于三项后期临床试验的推进、为计划中的产品上市储备商业库存,以及拓展商业运营体系与抗体寡核苷酸偶联药物(AOC)技术平台。

关于此次股票发行,Avidity Biosciences还向承销商授予了超额配售权:在发行日起30天内,可额外配售价值不超过7500万美元的股票。公司同时强调:“目前无法保证此次股票发行能否完成、何时完成,也无法保证发行的实际规模及条款。”

据了解,Avidity Biosciences是一家专注于AOC研发的生物制药公司,其核心业务是通过RNA疗法治疗罕见病和肌肉疾病。该公司目前拥有三条处于临床阶段的AOC管线,主要针对肌营养不良、杜氏肌营养不良(DMD)等遗传性肌肉疾病。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10